The launch of an innovative clinical trial testing the IMD10 focused ultrasound device alongside standard chemotherapy for challenging cases of pancreatic cancer was announced on January 10, 2026. This investigation seeks to explore improved outcomes for patients with borderline resectable or locally advanced pancreatic cancer. Sponsored by IMGT Co., Ltd., this trial has yet to begin recruiting participants.
In this article
- What changed?
- What is the IMD10 device?
- Trial design and objective
- Implications for medical device regulators and clinicians
- FAQ
- Conclusion
- Disclaimer
- Official announcement and link
What changed?
A clinical trial involving the IMD10 device combined with chemotherapy regimens for pancreatic cancer was recently announced. IMGT Co., Ltd., aims to evaluate whether adding focused ultrasound technology improves treatment outcomes for patients diagnosed with borderline resectable or locally advanced pancreatic cancer.
Patients in these categories face limited surgical options due to the tumor’s positioning or lack of resection feasibility. This trial could significantly influence future treatment pathways.
What is the IMD10 device?
The IMD10 is a novel focused ultrasound device intended to target pancreatic tumors precisely. It operates by leveraging advanced ultrasound technology to disrupt tumor cells, potentially improving chemotherapy delivery and effectiveness.
This approach represents a non-invasive adjunct to traditional therapies, offering promise for challenging oncological cases where resectability is limited or unavailable. However, details on its safety and efficacy in combination with chemotherapy remain under clinical investigation.
Trial design and objective
The trial’s sponsors plan to assess the efficacy and safety of combining IMD10 technology with a chemotherapy regimen consisting of irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU), and leucovorin. Specific outcomes will likely include progression-free survival rates, overall survival, and adverse events linked to IMD10 use.
Participants will be segregated into groups receiving only the chemotherapy regimen or both the chemotherapy and IMD10 treatments. This comparative model is expected to elucidate the potential added value of the medical device.
Who is eligible?
Screening criteria focus on individuals diagnosed with borderline resectable or locally advanced pancreatic cancer. Recruitment specifics, anticipated to include clinical inclusion and exclusion criteria, will be published shortly on the trial’s official registry.
Implications for medical device regulators and clinicians
The trial results will serve as a basis for evaluating the IMD10 device’s compliance with regulatory safety and performance standards, particularly under jurisdictions such as the U.S. FDA or MDR in the European Union.
For clinicians, this study could reshape treatment paradigms by integrating new technologies into complex pancreatic cancer cases. Transparent reporting and adherence to clinical trial protocols will remain critical in translating findings into practice.
FAQ
- When will the trial begin?
As of now, recruitment has not started. Details on commencement will be disclosed on ClinicalTrials.gov. - What are the potential benefits of using IMD10?
The device aims to enhance chemotherapy efficacy via focused ultrasound, offering non-invasive intervention in complex cancer scenarios. - Who sponsors this trial?
IMGT Co., Ltd. is the primary sponsor, leading regulatory and scientific oversight activities.
Conclusion
This upcoming trial highlights the potential integration of novel devices like IMD10 into oncology. With its focus on pancreatic cancer patients facing limited treatment options, the results could either validate or challenge traditional paradigms. Stakeholders, including clinicians and regulators, should monitor this study for its clinical and scientific insights.
Disclaimer
This content is informational and intended for healthcare professionals and regulatory experts. It does not constitute legal or medical advice.
Official announcement and link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07325214?term=medical+device